OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of ...

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / ...